Company Profile

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE4712.7041.65 (+0.89 % )
PREV CLOSE (Rs.) 4671.05
OPEN PRICE (Rs.) 4679.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 59196
TODAY'S LOW / HIGH (Rs.)4679.90 4802.00
52 WK LOW / HIGH (Rs.)4135.9 5613.65
NSE4711.20 38.55 (+0.83 % )
PREV CLOSE(Rs.) 4672.65
OPEN PRICE (Rs.) 4685.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 4711.20 (538 )
VOLUME 1373200
TODAY'S LOW / HIGH(Rs.) 4677.60 4805.00
52 WK LOW / HIGH (Rs.)4135 5614.6

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.03
Dividend Yield(%) 0.53
TTM EPS (Rs.) 99.16
P/E Ratio 47.53
Book Value (Rs.) 1038.14
Face Value (Rs.) 5
MCap (Rs. in Mn) 784005.40
Price/Earning (TTM) 31.56
Price/Sales (TTM) 5.85
Price/Book (MRQ) 4.54
PAT Margin (%) 16.38
ROCE (%) 17.81
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
28Jul07-28-2021$Dr Reddy's anticipates locally manufactured Sputnik V to be available from September-October period Dr Reddy's anticipates local

Dr Reddy's Laboratories is anticipating the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period. The local manufacturers are currently in the process of Technology absorption and scale up.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr Reddy's Laboratories is anticipating the locally manufacture..
28Jul07-28-2021$Dr Reddys Laboratories informs about disclosure Dr Reddys Laboratories infor
Dr Reddys Laboratories has informed that the Company has filed its unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended June 30, 2021, with the United States Securities and Exchange Commission on July 27, 2021. A copy of the Form 6- K is attached.

The above information is a part of company’s filings submitted to BSE.

Dr Reddys Laboratories has informed that the Company has filed..
28Jul07-28-2021$Dr. Reddy's Laboratories tumbles on reporting 36% fall in Q1 consolidated net profit Dr. Reddy's Laboratories tum

Dr. Reddys Laboratories is currently trading at Rs. 4706.35, down by 138.00 points or 2.85% from its previous closing of Rs. 4844.35 on the BSE.

The scrip opened at Rs. 4855.00 and has touched a high and low of Rs. 4875.85 and Rs. 4666.95 respectively. So far 1.28 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,613.65 on 07-Jul-2021 and a 52 week low of Rs. 4,019.65 on 28-Jul-2020.

Last one week high and low of the scrip stood at Rs. 5445.05 and Rs. 4666.95 respectively. The current market cap of the company is Rs. 88282.25 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.93% and 17.06% respectively.

Dr. Reddy's Laboratories has reported a fall of 56.49% in its net profit at Rs 413.40 crore for the quarter ended June 30, 2021 as compared to Rs 950.20 crore for the same quarter in the previous year. Total income of the company decreased by 6.93% at Rs 3619.70 crore for Q1FY22 as compared Rs 3889.10 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 36.02% in its net profit of associate at Rs 380.40 crore for the quarter ended June 30, 2021 as compared to Rs 594.60 crore for the same quarter in the previous year. However, total income of the company increased by 11.95% at Rs 5053.00 crore for Q1FY22 as compared Rs 4513.60 crore for the corresponding quarter previous year.

Dr. Reddys Laboratories is currently trading at Rs. 4706.35, do..
27Jul07-27-2021$Dr. Reddy's Laboratories reports 36% fall in Q1 consolidated net profit Dr. Reddy's Laboratories rep

Dr. Reddy's Laboratories has reported results for first quarter ended June 30, 2021.

The company has reported a fall of 56.49% in its net profit at Rs 413.40 crore for the quarter under review as compared to Rs 950.20 crore for the same quarter in the previous year. Total income of the company decreased by 6.93% at Rs 3619.70 crore for Q1FY22 as compared Rs 3889.10 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 36.02% in its net profit of associate at Rs 380.40 crore for the quarter under review as compared to Rs 594.60 crore for the same quarter in the previous year. However, total income of the company increased by 11.95% at Rs 5053.00 crore for Q1FY22 as compared Rs 4513.60 crore for the corresponding quarter previous year.

Dr. Reddy's Laboratories has reported results for first quarter..
27Jul07-27-2021$Dr.Reddy's Laboratories informs about board meeting proceedings Dr.Reddy's Laboratories info
Dr.Reddy's Laboratories has informed that the Board of Directors of the Company at their meeting held on July 27, 2021 have approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021. In terms of the above, it enclosed the following: Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter ended June 30, 2021 prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); Press Release on Financial Results of the Company for the above period; and etc.

The above information is a part of company’s filings submitted to BSE.

Dr.Reddy's Laboratories has informed that the Board of Director..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit413421864
Gross Profit 5445 30562
Operating Profit 748139379
Net Sales 34335133491
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 19086.15 (4.92%)
M.Cap ( in Cr)
40556.74
Sanofi India (BSE)
 8367.90 (3.43%)
M.Cap ( in Cr)
19271.79
Alkem Laboratories (BSE)
 3454.55 (3.70%)
M.Cap ( in Cr)
41304.33
Sun Pharma Inds. (BSE)
 774.00 (10.06%)
M.Cap ( in Cr)
185708.53
Divi's Lab (BSE)
 4904.65 (1.20%)
M.Cap ( in Cr)
130203.05
Shareholding Pattern More
PROMOTERS 26.73 %
FI/BANKS/INSURANCE 2.66 %
NON-INSTITUTION 16.4 %
MUTUAL FUNDS/UTI 12.42 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes